News
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried
Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
IMV Inc. Announces Second Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent
Epigenomics: Aktie knallt nach Studiennews – so geht es weiter!
Neue medizinische Erkenntnisse sorgen für frischen Schwung im Handel mit Epigenomics-Aktien (WKN: A11QW5). Die Ergebnisse der im "Journal of the National Cancer Institute" (JNCI) erschienenen Studie
Pfenex mit +109% in 3 Monaten: Nächster Buyout für den NBC!
Mit Pfenex (WKN: A118RA) meldet die Mai-Empfehlung des No Brainer Clubs ein lukratives Übernahmeangebot. NBC-Mitglieder liegen damit in nur drei Monaten mindestens +109% vorne.
Anfang Mai empfahlen
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Medigene berichtet über 2. Quartal und veröffentlicht Halbjahresbericht 2020
Telefonkonferenz heute, 7. August 2020 um 14.00 Uhr MEZ (in englischer Sprache)
Unternehmensmitteilung für den Kapitalmarkt
Martinsried/München (07.08.2020) - Die Medigene AG (Medigene,
Medigene provides Q2 update and 6M report 2020
Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)
Business news for the stock market
Martinsried/ Munich (07.08.2020) - Medigene AG (Medigene, FSE: MDG1, Prime
Clovis Oncology Announces Second Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and
Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
“With a final design for
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
Puma Biotechnology Reports Second Quarter 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the
Biofrontera: Die US-Zocker drehen jetzt völlig durch!
Aufgrund der Covid-19-Pandemie bedingten Wirtschaftskrise gibt es in den USA plötzlich ein Sozialsystem. Welch seltsame Blüten dies treibt, zeigt sich nun ausgerechnet beim deutschen
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
“We are very excited about our global
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its
EnWave unterzeichnet kommerziellen Lizenz- und Gerätekaufvertrag mit Orto Al Sole für Nutzung der REV™ Technologie in Italien
Vancouver, B.C., 5. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab